


PRESS RELEASE

Grenchen, April 29, 2016

Breaking news: angiogenic potential of INICELL®

A recent study performed at the ETH Zürich and published in Nature Scientific Reports demonstrates that INICELL®, Thommen Medical's implant surface, upregulates the secretion of major factors associated with fast healing. Such factors include matrix metalloproteinases (MMPs), which break down the extracellular matrix, and the growth factor VEGF, which is known for its angiogenic potential. Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels, it is a normal and vital process in wound healing. Sufficient blood supply is the precondition for new bone formation, which is in turn the precondition for fast osseointegration of implants.

These research results demonstrate the unsurpassed potential of the INICELL® implant surface for rapid and sustained integration of implants in bone.



Illustrated representation of how fibroblasts and a Ti surface-adhering blood clot synergistically upregulate remodelling capacity and angiogenic potential (Ti surface = INICELL®).

For more information on the publication in Nature Scientific Report about INICELL®:

Synergistic interactions of blood borne immune cells, fibroblasts and extracellular matrix drive repair in an *in vitro* peri-implant wound healing model

Melanie A Burkhardt, Jasmin Waser, Vincent Milleret, Isabel Gerber, Maximilian Y Emmert, Jasper Foolen, Simon P Hoerstrup, Falko Schlottig, Viola Vogel

Scientific Reports | 6:21071 | DOI: 10.1038/srep21071 /

<http://www.nature.com/articles/srep21071>

INICELL® is just one example of the motivation at the center of Thommen Medical's research activities, which is their commitment to the needs of clinicians and their patients, so that Thommen Medical may provide clinicians with the ideal environment for delivering their best results.

Contact

Thommen Medical AG
Neckarsulmstrasse 28
CH-2540 Grenchen
Tel. +41 61 965 90 20
Fax +41 61 965 90 21
presse@thommenmedical.com
www.thommenmedical.com

The press release is also available online:

<http://www.thommenmedical.com/en/company/media/press-releases.html>

About Thommen Medical

Thommen Medical develops, manufactures and sells high-quality products for dental implantology, mainly the Thommen Implant System and biomaterials. Swiss precision, innovation, and functional design form the basis for all of the company's products. Thommen Medical's headquarters and private manufacturing facility is located in Grenchen, Switzerland. Thommen Medical has subsidiaries in Switzerland, Germany, Austria, United States and Canada, and is represented by distribution partners in most other major markets of Europe, Asia and the Middle East. It is currently a privately held company, with two private investor groups and Novartis being the majority stockholders.